Microbiological outcome of complicated urinary tract infections treated with levofloxacin: A pharmacokinetic/pharmacodynamic analysis

International Journal of Antimicrobial Agents

Volumn 35, Issue 6, 2010, Pages 573-577

  Deguchi, Takashi ^a   Nakane, Keita ^a   Yasuda, Mitsuru ^a   Shimizu, Takako ^b   Monden, Koichi ^c   Arakawa, Soichi ^d   Matsumoto, Tetsuro ^e  

^a GIFU UNIVERSITY   (Japan)

^b DAIICHI SANKYO CO   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

^d KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Complicated urinary tract infection; Levofloxacin; Pharmacodynamics; Pharmacokinetics

Indexed keywords

LEVOFLOXACIN;

AGED; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG URINE LEVEL; ENTEROCOCCUS FAECALIS; ERADICATION THERAPY; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE COCCI; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; TREATMENT DURATION; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; COMPUTER SIMULATION; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; SERUM; TREATMENT OUTCOME; URINARY TRACT INFECTIONS; URINE;

EID: 77951766133     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.02.004     Document Type: Article

References (21)

1. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26:1-10.
2. Rybak M.J. Pharmacodynamics: relation to antimicrobial resistance. Am J Infect Control 2006, 34(Suppl. 1):S38-S45.
3. Craig W.A. Does the dose matter?. Clin Infect Dis 2001, 33(Suppl. 3):S233-S237.
4. Forrest A., Nix D.E., Ballow C.H., Goss T.F., Birmingham M.C., Schentag J.J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993, 37:1073-1081.
5. Ambrose P.G., Grasela D.M., Grasela T.H., Passarell J., Mayer H.B., Pierce P.F. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001, 45:2793-2797.
6. Zelenitsky S.A., Harding G.K., Sun S., Ubhi K., Ariano R.E. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimicrob Chemother 2003, 52:668-674.
7. Drusano G.L., Preston S.L., Fowler C., Corrado M., Weisinger B., Kahn J. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004, 189:1590-1597.
8. Stamey T.A., Fair W.R., Timothy M.M., Millar M.A., Mihara G., Lowery Y.C. Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections. N Engl J Med 1974, 291:1159-1163.
9. Miller L.G., Mehrotra R., Tang A.W. Does in vitro fluoroquinolone resistance predict clinical failure in urinary tract infections?. Int J Antimicrob Agents 2007, 29:605-607.
10. Frimodt-Møller N. Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int J Antimicrob Agents 2002, 19:546-553.
11. Wagenlehner F.M., Weidner W., Naber K.G. Emergence of antibiotic resistance amongst hospital-acquired urinary tract infections and pharmacokinetic/pharmacodynamic considerations. J Hosp Infect 2005, 60:191-200.
12. Matsumoto T., Yasuda M., Arakawa S., Monden K., Muratani T., Hori S. Clinical response of levofloxacin 500mg qd to complicated urinary tract infection-efficacy of 7- and 14-day administration. Jpn J Chemother 2009, 57(Suppl. 2):34-46.
13. Tanigawara Y., Shimizu T., Totsuka K. Population pharmacokinetics and pharmacodynamics of 500mg oral dose levofloxacin in respiratory tract infection patients. Jpn J Chemother 2009, 57(Suppl. 2):47-54.
14. Wagenlehner F.M.E., Kinzig-Schippers M., Sörgel F., Weidner W., Naber K.G. Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500mg) versus ciprofloxacin (500mg) in healthy volunteers receiving a single oral dose. Int J Antimicrob Agents 2006, 28:551-559.
15. Naightingale C.H., Grant E.M., Quintiliani R. Pharmacodynamics and pharmacokinetics of levofloxacin. Chemotherapy 2000, 46(Suppl. 1):6-14.
16. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Seventeenth informational supplement. Document M100-S17. Wayne, PA: CLSI; 2007.
17. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints. Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases. [accessed 10 February 2010]. http://www.eucast.org/clinical_breakpoints/.
18. Wright D.H., Brown G.H., Peterson M.L., Rotschafer J.C. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 2000, 46:669-683.
19. Stein G.E., Schooley S.L., Nicolau D.P. Urinary bacterial activity of single doses (250, 500, 750 and 1000mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli. Int J Antimicrob Agents 2008, 32:320-325.
20. Wagenlehner F.M.E., Kinzig-Schippers M., Tischmeyer U., Wagenlehner C., Sörgel F., Naber K.G. Urinary bactericidal activity of extended-release ciprofloxacin (1,000 milligrams) versus levofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. Antimicrob Agents Chemother 2006, 50:3947-3949.
21. Wagenlehner F.M.E., Wagenlehner C., Redman R., Weidner W., Naber K.G. Urinary bactericidal activity of doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. Antimicrob Agents Chemother 2009, 53:1567-1573.